Business Context and Reporting Period
Company: BioLife Solutions, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2015
Business Overview: BioLife is a developer and marketer of clinical-grade cell and tissue hypothermic storage and cryopreservation media (HypoThermosol and CryoStor platforms). The company also operates a joint venture, biologistex, focused on cloud-hosted biologistics cold chain management and "smart shippers."
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2015 | Nine Months Ended Sept 30, 2015 |
|---|---|---|
| Product Sales (Revenue) | $1,631,926 | $4,629,407 |
| Gross Profit | $973,384 | $2,674,655 |
| Gross Margin | 60% | 58% |
| Operating Loss | $(1,296,448) | $(3,612,827) |
| Net Loss (Consolidated) | $(1,291,719) | $(3,594,379) |
| Net Loss Attributable to BioLife | $(1,068,688) | $(3,094,549) |
| Cash and Cash Equivalents | $2,351,540 | $2,351,540 (Balance Sheet) |
| Short-Term Investments | $2,902,105 | $2,902,105 (Balance Sheet) |
| Total Liquidity (Cash + ST Inv) | $5,253,645 | $5,253,645 |
| Total Liabilities | $2,441,176 | $2,441,176 |
| Net Cash Used in Operating Activities | N/A | $(3,703,591) |
Material Changes vs. Prior Period
- Revenue Growth: Product sales increased 31% in Q3 2015 compared to Q3 2014, driven by a 38% increase in direct sales to regenerative medicine customers and over 100% growth in hair transplantation sales. Year-to-date revenue increased 2% primarily due to a 32% increase in biopreservation media sales, partially offset by a 92% decline in low-margin contract manufacturing services.
- Margin Expansion: Gross margin improved significantly to 60% in Q3 2015 (from 47% in Q3 2014) and 58% for the nine months (from 45% in 2014). This was driven by higher sales of high-margin media products and reduced low-margin contract manufacturing revenue.
- Expense Increases: Operating expenses rose 55% in Q3 and 51% year-to-date. Research and Development (R&D) expenses increased 115% (Q3) and 86% (YTD), while Sales and Marketing expenses increased 127% (Q3) and 125% (YTD). These increases are attributed to higher headcount, salary adjustments, and launch costs for the biologistex joint venture.
- Net Loss Widening: The consolidated net loss increased to $1.3 million in Q3 2015 from $0.9 million in Q3 2014, and to $3.6 million for the nine months from $2.3 million in the prior year period, primarily due to increased spending on the biologistex launch.
Guidance, Outlook, and Risks
- Outlook: Management estimates biopreservation media product revenue will grow 20% to 30% in 2015 compared to 2014. Full-year gross margin is expected to range between 55% and 60%.
- Liquidity: As of September 30, 2015, the company held approximately $5.3 million in cash and short-term investments. Management expects this to be sufficient to meet liquidity needs through 2016, subject to strategic transactions.
- Key Initiatives: The company commercially launched the biologistex cold chain management app and began shipping evo Smart Shippers. A new product, BloodStor 27 NaCl Freeze Media, was also launched.
- Risks and Contingencies:
- Customer Concentration: Approximately 10% of Q3 2015 revenue was derived from a single customer. Two customers accounted for 26% of gross accounts receivable.
- Joint Venture Commitments: The biologistex joint venture has a remaining purchase commitment of $2.2 million for Smart Containers and has recorded $0.8 million of a $1.0 million participation fee commitment to SAVSU.
- Capital Requirements: The company continues to monitor opportunities for acquisitions or strategic transactions, which may require additional debt or equity financing.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $3.7 million net cash used in operating activities for the nine-month period against the $5.3 million liquidity position.
- Revenue Mix: Confirm the continued decline in low-margin contract manufacturing revenue and the sustainability of the 31% growth in core biopreservation media sales.
- Joint Venture Costs: Monitor the impact of the biologistex launch on operating expenses, specifically the $0.3 million to $0.5 million in participation fees and marketing costs.
- Customer Concentration: Assess the risk associated with the top customer representing 10% of revenue and the top two customers representing 26% of receivables.
- Capitalized Software: Review the $1.2 million capitalized for internal use software (biologistex) and the timeline for amortization once commercially deployed.